ATE293960T1 - Transdermale vorrichtung zur verabreichungvon von testosteron - Google Patents

Transdermale vorrichtung zur verabreichungvon von testosteron

Info

Publication number
ATE293960T1
ATE293960T1 AT98911439T AT98911439T ATE293960T1 AT E293960 T1 ATE293960 T1 AT E293960T1 AT 98911439 T AT98911439 T AT 98911439T AT 98911439 T AT98911439 T AT 98911439T AT E293960 T1 ATE293960 T1 AT E293960T1
Authority
AT
Austria
Prior art keywords
testosterone
administration
transdermal device
transdermal
terpene
Prior art date
Application number
AT98911439T
Other languages
English (en)
Inventor
John C Hedenstrom
Michael L Husberg
Shari L Myszka
Matthew T Scholz
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE293960T1 publication Critical patent/ATE293960T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT98911439T 1997-02-28 1998-02-27 Transdermale vorrichtung zur verabreichungvon von testosteron ATE293960T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3927497P 1997-02-28 1997-02-28
PCT/US1998/003943 WO1998037871A1 (en) 1997-02-28 1998-02-27 Transdermal device for the delivery of testosterone

Publications (1)

Publication Number Publication Date
ATE293960T1 true ATE293960T1 (de) 2005-05-15

Family

ID=21904596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98911439T ATE293960T1 (de) 1997-02-28 1998-02-27 Transdermale vorrichtung zur verabreichungvon von testosteron

Country Status (16)

Country Link
US (1) US6132760A (de)
EP (1) EP0979072B1 (de)
JP (1) JP2001517216A (de)
KR (1) KR20000075804A (de)
AT (1) ATE293960T1 (de)
AU (1) AU735944B2 (de)
BR (1) BR9807786A (de)
CA (1) CA2281876A1 (de)
DE (1) DE69829961T2 (de)
HU (1) HUP0001748A3 (de)
NO (1) NO994042L (de)
NZ (1) NZ337135A (de)
PL (1) PL335410A1 (de)
SK (1) SK116199A3 (de)
TR (1) TR199902104T2 (de)
WO (1) WO1998037871A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US9056060B2 (en) * 2000-09-19 2015-06-16 Henkel Ag & Co. Kgaa Non-reactive adhesive useful in transdermal drug delivery system
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
EP1392272B1 (de) * 2001-05-11 2014-08-06 Merrion Research III Limited Permeationsverbesserer
KR100517637B1 (ko) * 2001-12-21 2005-09-28 씨제이 주식회사 섬수 정제 엑스 및 인삼 정제 엑스를 함께 함유하면서다른 정유 생약 성분은 함유하지 않는 조루증의 예방 및치료용 조성물
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
RS20050812A (sr) 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
CA2529852A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
JP4567998B2 (ja) * 2004-03-22 2010-10-27 コスメディ製薬株式会社 親水性粘着剤を用いた親水性皮膚外用粘着剤組成物および親水性貼付剤
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
FR2924942B1 (fr) * 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
US8445037B2 (en) * 2008-10-28 2013-05-21 A. M. Todd Company Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest
EP2640398A4 (de) 2010-11-18 2014-05-14 White Mountain Pharma Inc Verfahren zur behandlung chronischer bzw. nicht linderbarer schmerzen und/oder erhöhung der schmerzschwelle bei einem patienten und pharmazeutische zusammensetzung zur verwendung darin
US20170007464A1 (en) * 2013-12-20 2017-01-12 3M Innovative Properties Company Antimicrobial pressure-sensitive adhesive system
UY35923A (es) * 2013-12-30 2015-07-31 Rhodia Operations ?composiciones pesticidas agrícolas?.
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622162B2 (en) * 1988-04-22 1992-04-02 Ciba-Geigy Ag Transdermal monolith systems
AU6712090A (en) * 1989-10-13 1991-05-16 Watson Laboratories, Inc. Drug delivery systems and matrix therefor
ATE143603T1 (de) * 1990-03-30 1996-10-15 Yasunori Morimoto Transdermal absorbierbares mittel mit morphin hydrochlorid
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
EP0491076A1 (de) * 1990-12-19 1992-06-24 Theratech, Inc. Penetrationsförderung mittels eines Mehrkomponentensystems aus N-aliphatischen Pyrrolidonen und niederen Alkoholen
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
JP3548195B2 (ja) * 1993-05-27 2004-07-28 リンテック株式会社 経皮吸収型製剤
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤

Also Published As

Publication number Publication date
KR20000075804A (ko) 2000-12-26
SK116199A3 (en) 2000-01-18
DE69829961T2 (de) 2006-02-23
HUP0001748A3 (en) 2001-03-28
JP2001517216A (ja) 2001-10-02
AU735944B2 (en) 2001-07-19
US6132760A (en) 2000-10-17
CA2281876A1 (en) 1998-09-03
EP0979072A1 (de) 2000-02-16
EP0979072B1 (de) 2005-04-27
NZ337135A (en) 2001-07-27
WO1998037871A1 (en) 1998-09-03
BR9807786A (pt) 2000-02-22
DE69829961D1 (de) 2005-06-02
PL335410A1 (en) 2000-04-25
NO994042L (no) 1999-10-26
HUP0001748A2 (hu) 2000-12-28
NO994042D0 (no) 1999-08-20
TR199902104T2 (xx) 2000-04-21
AU6539098A (en) 1998-09-18

Similar Documents

Publication Publication Date Title
ATE293960T1 (de) Transdermale vorrichtung zur verabreichungvon von testosteron
DK0973497T3 (da) Farmaceutisk bæreanordning, egnet til udlevering af farmaceutiske forbindelser til slimhindeoverflade
WO1999012529A3 (de) Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
DE69426988D1 (de) Transdermale abgabe vorrichtung
HUP9901991A2 (hu) Transzdermális eszköz flurbiprofén átadására
AU2895392A (en) Transdermal therapeutic systems containing crystallization inhibitors
WO1998055079A3 (en) A delivery system for an oral care substance using a strip of material having low flexural stiffness
ATE163854T1 (de) Dexpanthenol-haltiges pflaster zur transdermalen applikation von steroidhormonen
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
ATE208200T1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
NO20000814L (no) Identifikasjon for klebende flateformede dermale og transdermale terapeutiske administrasjonsformer under anvendelse av et klebende plaster som informasjonsbærer, såvel som fremgangsmåte for deres fremstilling
DE59712215D1 (de) Transdermales therapeutisches system mit einer östriol enthaltenden bisphosphatekombination

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties